StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note issued to investors on Friday. The brokerage issued a sell rating on the medical research company’s stock.
Organovo Price Performance
ONVO stock opened at $1.00 on Friday. Organovo has a fifty-two week low of $0.89 and a fifty-two week high of $2.05. The business’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.12.
Organovo (NASDAQ:ONVO – Get Free Report) last posted its earnings results on Thursday, February 8th. The medical research company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.08 million. Equities research analysts forecast that Organovo will post -1.74 earnings per share for the current fiscal year.
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
See Also
- Five stocks we like better than Organovo
- The Role Economic Reports Play in a Successful Investment Strategy
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- How to Most Effectively Use the MarketBeat Earnings Screener
- MarketBeat Week in Review – 4/22 – 4/26
- What is a Dividend King?
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
